The global microbiome therapeutics market is projected to reach USD 1,066.8 million by 2030, growing at a compound annual growth rate (CAGR) of 35.32% from 2023 to 2030, as per a new report by Grand View Research, Inc. The growth in the market is primarily driven by the increasing prevalence of diseases that target the gastrointestinal system, diabetes, and immunological conditions. One of the major advancements is the adoption of fecal microbiota transplant (FMT), with FMT now available in capsule form. This has enhanced the acceptance of microbiome therapeutics, particularly among patients suffering from C. difficile infections. In addition, rising research and development (R&D) investments, as well as government support, are expected to propel market growth further.

FMT has shown significant success in treating patients with recurrent C. difficile infection. The growing prevalence of this condition is likely to increase the demand for microbiome therapies. For example, according to the Therapeutic Advancements in Gastroenterology Journal, between 25% and 65% of patients in the U.S. who experience an initial occurrence of C. difficile infection (CDI) face recurrent infections, making treatment more complex and underscoring the need for effective therapies.

There is also a growing emphasis on understanding the human microbiome in order to harness its therapeutic potential. This has led to a surge in R&D efforts, resulting in a stronger product pipeline in the market. For instance, candidates such as CH-0601 and M-008 are currently under development for treating diabetes. Additionally, companies in the sector are receiving increased funding from investors, as interest in microbiome-based therapies continues to rise. A notable example of this is Vedanta Biosciences, which received USD 68 million in funding in July 2021 for the phase III development of its product, VE303, for treating high-risk CDI.

Get a preview of the latest developments in the Microbiome Therapeutics Market? Download your FREE sample PDF copy today and explore key data and trends. 

FAQ for the Global Microbiome Therapeutics Market

1. What is the global microbiome therapeutics market size?

The global microbiome therapeutics market is expected to reach USD 1,066.8 million by 2030, growing at a CAGR of 35.32% from 2023 to 2030.

2. What are the key drivers of growth in the microbiome therapeutics market?

The market growth is driven by the increasing prevalence of gastrointestinal diseases, diabetes, and immunological disorders. Additionally, the rise in the adoption of fecal microbiota transplants (FMT) and advancements in drug delivery systems have significantly enhanced the acceptance of microbiome therapeutics, particularly for conditions like C. difficile infections.

3. How has fecal microbiota transplant (FMT) contributed to the market?

FMT has demonstrated considerable success in treating patients with recurrent C. difficile infections. The growing prevalence of C. difficile infection is expected to further drive the demand for microbiome therapies. The availability of FMT in capsule form has also increased patient acceptance and made treatment more accessible.

4. What is the impact of research and development (R&D) on the microbiome therapeutics market?

Increasing investments in R&D and growing interest in the therapeutic potential of the human microbiome are key factors driving market growth. This has led to the development of a stronger pipeline of microbiome-based therapeutic products. Several new candidates, such as CH-0601 and M-008, are under development for treating diabetes and other chronic diseases.

5. What are some notable developments in the microbiome therapeutics market?

In 2021, Ferring Pharmaceuticals and Rebiotix announced Phase III trial data for their candidate, RBX2660, aimed at reducing recurrent C. difficile infections. The product has received fast track, orphan, and breakthrough therapy designations from the FDA, accelerating its path to market.

6. What is the significance of microbiome research in therapeutic applications?

Research into the human microbiome is essential for understanding its role in health and disease. This understanding opens up new avenues for treating a variety of conditions by harnessing the microbiome's potential to restore balance and improve patient outcomes.

Order a free sample PDF of the Microbiome Therapeutics Market Intelligence Study, published by Grand View Research.